Pharmacokinetic Characterization of Intramuscular Olanzapine Depot

Eli Lilly and Company

Overview

The goals of this study are to: Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different points in time after an injection, and compare these levels to the amount of olanzapine in the blood of patients after treated by oral administration with Zyprexa (olanzapine) tablets or by intramuscular administration with Zyprexa IntraMuscular (olanzapine for injection).

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Schizophrenia Schizoaffective Disorder

Interventions

Intramuscular Olanzapine DepotDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 76 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have schizophrenia or schizoaffective disorders. * Each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent. * Patient must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry. * Female patients must not be pregnant or breast-feeding. * Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or schizoaffective disorder.

Locations (8)

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.

Adelaide, South Australia, Australia

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.